Revenues - (Tables)

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Summary of disaggregation of revenue

The following table presents a summary of total revenues (in thousands): 

	Three Months Ended March 31,
	2020		2019
Xyrem	$	407,875	$	368,317
Erwinaze/Erwinase	37,732		60,899
Defitelio/defibrotide	47,432		41,500
Vyxeos	32,720		28,943
Sunosi	1,924		—
Other	2,522		3,672
Product sales, net	530,205		503,331
Royalties and contract revenues	4,521		4,855
Total revenues	$	534,726	$	508,186

The following table presents a summary of total revenues attributed to geographic sources (in thousands): 

	Three Months Ended March 31,
	2020		2019
United States	$	478,483	$	462,862
Europe	41,556		35,401
All other	14,687		9,923
Total revenues	$	534,726	$	508,186

Summary of Revenues from Customers Representing More Than 10% of Total Revenues

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: 

	Three Months Ended March 31,
	2020		2019
ESSDS	76	%	72	%
McKesson	13	%	18	%

Summary of a reconciliation in contract liabilities from contracts with customer

The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers for the three months ended March 31, 2020 (in thousands): 

	Contract Liabilities
Balance as of December 31, 2019	$	9,581
Amount recognized within royalties and contract revenues	(1,180		)
Balance as of March 31, 2020	$	8,401